NCT03005119 - Evaluation of the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in MS Patients With Spasticity-related Symptoms | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions

Multiple Sclerosis

Interventions

DRUG

PTL201

Two piece acid resistance hard capsule filled with seamless gelatin matrix green beads containing tetrahydrocannabinol (THC) and cannabidiol (CBD). Each capsule contain 5 mg THC and 5 mg CBD

DRUG

Placebo Oral Capsule

Placebo seamless gelatin matrix green beads containing excipients only

Trial Locations (1)

Unknown

Sheba medical center, Tel Hashomer, Ramat Gan